Targovax AS Announces First Patient Included In Phase I/II Clinical Study With The Therapeutic Cancer Vaccine TG01 In Operable Pancreatic Cancer
TG01 has received Orphan Drug Status for pancreatic cancer in EU and USA. Targovax owns patents and the documentation from earlier development of TG01.
The Norwegian Radium Hospital, Clinical Cancer Research Unit, Svein Dueland: +47-915-02770SOURCE Targovax AS
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts